Saturday 17 October 2026 Export MCK’s income statement to Excel — free account

McKesson Corporation

McKesson Corporation’s revenue for fiscal 2026 (year ended March 2026) was $403.4 billion, up 12.4% from fiscal 2025. In the quarter to June 2026, revenue grew 7.72%, EPS fell 17.7%, free cash flow grew 66.4% and total debt rose 10.5%, each against the same quarter a year earlier. Member of the S&P 500; dividend growth for twenty-five consecutive years, revenue growth for ten.

1,006.92 8.28 +0.83%

Follow MCK

Alert me

Market cap: $116.4B
P/E: 26.8×
Fwd P/E: 18.3×
Dividend yield: 0.34%
F-score: 7/9
Altman Z: 6.15
Beneish M: −2.34
Dividend safety: 86/100

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios Filings 10-Q 10-K

Insider Decisions trades per month

Total sells 28.27

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	1	—	1	4	1	—	2	5	1	1	1	—

Insider Ownership 1.84%

Capital & Financial Ratios $m

Market Cap 116,430.00

Revenue 410,983.00

Net Income 5,300.00

Free Cash Flow 6,145.00

Net Debt 9,623.00

Current Ratio 0.89

Debt/Equity (3.83)

P/E ratio 26.83

Fwd P/E 18.30

P/S ratio 0.29

P/B ratio 0.00

Past 5Y EPS Growth —

This Y EPS Growth 14.17%

Next Y EPS Growth 13.48%

Next Y revenue growth 7.05%

Next 5Y EPS Growth 14.10%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 66.06%

10-year low 10-year high

P/S against its own 10 years 99.26%

10-year low 10-year high

EV/Sales against its own 10 years 99.45%

10-year low 10-year high

EV/FCF against its own 10 years 90.45%

10-year low 10-year high

Dividends

Payout Ratio 0.09

Annual Dividend Rate 3.40

Annual Dividend Yield 0.34%

	total	individual payouts
2029	Powerpack
2028	Powerpack
2027	Powerpack
2026	2.58	0.82 0.82 0.94
2025	3.06	0.71 0.71 0.82 0.82
2024	2.66	0.62 0.62 0.71 0.71
2023	2.32	0.54 0.54 0.62 0.62
2022	2.02	0.47 0.47 0.54 0.54
2021	2.20	0.42 0.42 0.42 0.47 0.47
2020	1.66	0.41 0.41 0.42 0.42
2019	1.60	0.39 0.39 0.41 0.41
2018	1.46	0.34 0.34 0.39 0.39
2017	1.24	0.28 0.28 0.34 0.34
2016	1.12	0.28 0.28 0.28 0.28

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	4,583	5,691	3,975	5,164
Receivables	21,622	25,643	27,985	30,316
Inventory	21,139	23,001	24,207	26,259
Other	—	—	—	—
	47,970	55,398	57,210	62,837

	2024	2025	2026	Q'26
Payables	47,097	55,330	59,973	63,731
ST’ Debt	50	1,191	1,267	1,297
Other	—	—	—	—
	52,357	61,604	67,017	70,356

Compound Annual Growth %

	10y	5y	3y
Sales	7.77%	11.11%	13.39%
Cash Flow	5.30%	6.27%	6.06%
Earnings	7.75%	0.00%	10.18%
Book Value	0.00%	0.00%	0.00%

Revenue $m

	Jun	Sep	Dec	Mar	Year
’26	105,380	—	—	—	—
’26	97,827	103,150	106,158	96,295	403,430
’25	79,283	93,651	95,294	90,823	359,051
’24	74,483	77,215	80,898	76,355	308,951
’23	67,154	70,157	70,490	68,910	276,711
’22	62,674	66,576	68,614	66,102	263,966
’21	55,679	60,808	62,599	59,142	238,228

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(220)	—	—	—	—
’26	(918)	2,420	1,232	3,421	6,155
’25	(1,380)	2,100	(2,383)	7,748	6,085
’24	(1,052)	965	254	4,147	4,314
’23	(941)	1,107	1,668	3,325	5,159
’22	(1,622)	1,792	1,377	2,887	4,434
’21	(1,062)	1,021	1,213	3,370	4,542

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	(372)	—	—	—	—
’26	(1,107)	2,224	1,057	3,236	5,410
’25	(1,547)	1,882	(2,579)	7,470	5,226
’24	(1,176)	825	100	3,878	3,627
’23	(1,041)	985	1,514	3,143	4,601
’22	(1,781)	1,672	1,276	2,732	3,899
’21	(1,179)	873	1,051	3,156	3,901

Fiscal quarters ending in the months shown.

EPS $

	Jun	Sep	Dec	Mar	Year
’26	5.15	—	—	—	—
’26	6.25	8.92	9.59	13.71	38.38
’25	7.00	1.87	6.95	10.01	25.72
’24	7.02	4.92	4.42	6.02	22.39
’23	5.32	6.42	7.66	5.71	25.03
’22	3.07	1.71	(0.04)	2.47	7.23
’21	2.72	3.54	(39.03)	4.15	(28.26)

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	133.82	106.11	109.16	112.60	169.34	237.61	331.75	462.70	565.75	723.68	Analyst estimates 2027–2029 Powerpack
	High	169.29	178.86	154.79	187.67	251.04	401.78	476.35	637.51	895.58	1,014.99
People
People	Employees	78,000	78,000	80,000	80,000	76,000	75,000	51,000	51,000	45,000	43,000
	Revenue/emp, $m	2.55	2.67	2.68	2.89	3.13	3.52	5.43	6.06	7.98	9.38
Income, $m
Income, $m	Revenue	198,533	208,357	214,319	231,051	238,228	263,966	276,711	308,951	359,051	403,430
	Gross margin, %	5.68	5.37	5.48	5.20	5.10	4.97	4.47	4.15	3.71	3.61
	EBT	6,891	239	610	1,144	(5,034)	1,928	4,630	3,789	4,359	6,201
	EBT margin, %	3.47	0.11	0.28	0.50	(2.11)	0.73	1.67	1.23	1.21	1.54
	Net income	5,153	297	255	1,120	(4,340)	1,287	3,722	3,160	3,481	5,099
	Depreciation	1,200	3,168	3,028	1,061	1,129	760	608	635	636	729
Per share, $
Per share, $	Revenue	898.34	1,001.72	1,091.79	1,279.35	1,483.36	1,733.20	1,961.10	2,319.45	2,818.30	3,264.00
	Earnings	22.95	0.32	0.17	4.98	(28.26)	7.32	25.23	22.54	25.86	38.55
	Cash flow	21.47	20.89	20.56	24.22	28.28	29.11	36.56	32.39	47.76	49.80
	Capex	(2.54)	(2.79)	(2.84)	(2.80)	(3.99)	(3.51)	(3.95)	(5.16)	(6.74)	(6.03)
	Free cash flow	18.92	18.10	17.72	21.42	24.29	25.60	32.61	27.23	41.02	43.77
	Book value	51.01	48.35	42.22	29.40	1.09	(11.77)	(10.56)	(12.00)	(13.30)	(14.38)
	Shares, m	221	208	196	181	161	152	141	133	127	124
Valuation, ×
Valuation, ×	P/E	6.29	607.87	1,485.50	26.06	0.00	41.94	14.13	23.81	25.92	22.40
	P/S	0.17	0.14	0.11	0.11	0.13	0.18	0.18	0.23	0.24	0.27
	P/B	2.91	2.89	2.82	4.60	178.99	0.00	0.00	0.00	0.00	0.00
	EV/Sales	0.19	0.16	0.13	0.12	0.17	0.21	0.21	0.25	0.25	0.28
	EV/FCF	9.21	9.11	8.03	7.19	10.32	14.41	12.56	21.68	17.47	21.18
Cash, $m
Cash, $m	Operating cash flow	4,744	4,345	4,036	4,374	4,542	4,434	5,159	4,314	6,085	6,155
	Capex	(562)	(580)	(557)	(506)	(641)	(535)	(558)	(687)	(859)	(745)
	Free cash flow	4,182	3,765	3,479	3,868	3,901	3,899	4,601	3,627	5,226	5,410
Balance, $m
Balance, $m	Working capital	1,336	451	839	(402)	1,279	(2,235)	(3,665)	(4,387)	(6,206)	(9,807)
	Total debt	8,545	7,880	7,595	7,387	15,215	13,099	12,219	11,742	11,255	11,617
	Net debt	5,762	5,208	4,614	3,372	8,937	9,567	7,541	7,159	5,564	7,642
	Shareholders’ equity	11,273	10,057	8,287	5,309	175	(1,792)	(1,490)	(1,599)	(1,694)	(1,777)
Returns, %
Returns, %	ROA	8.63	0.11	0.06	1.49	(7.19)	1.74	5.67	4.63	4.62	6.05
	ROIC	26.13	3.12	4.29	17.92	(34.57)	16.38	45.25	43.94	71.41	66.20
	ROE	50.00	0.63	0.37	13.24	(165.54)	(137.79)	(216.94)	(194.37)	(200.12)	(274.39)

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MCK McKesson Corporation	$116.4B	26.8×	18.3×	+7.72% (above 0%: growing)	−17.68% (below 0%: shrinking)	+66.40% (above 0%: growing)	3.50%	1.25%
COR Cencora, Inc.	$65.2B	25.2×	14.5×	+5.07% (above 0%: growing)	+11.27% (above 0%: growing)	+3,385.25% (above 0%: growing)	4.26%	1.32%	Compare
CAH Cardinal Health, Inc.	$58.8B	35.0×	23.3×	+5.84% (above 0%: growing)	+68.32% (above 0%: growing)	+10.87% (above 0%: growing)	4.02%	1.14%	Compare
HSIC Henry Schein, Inc.	$9.7B	25.0×	18.5×	+6.73% (above 0%: growing)	+16.90% (above 0%: growing)	+140.91% (above 0%: growing)	31.84%	4.95%	Compare
AHG Akso Health Group Sponsored ADR	$1.2B	— (loss-making)	— (loss-making)	+263.89% (above 0%: growing)	n/m	−12,975.04% (below 0%: shrinking)	0.00%	0.00%	Compare
FOCL FocalTherics	$154.8M	— (loss-making)	— (loss-making)	+38.85% (above 0%: growing)	n/m	+21.49% (above 0%: growing)	55.59%	(60.83%)	Compare
COSM Cosmos Health Inc.	$33.9M	— (loss-making)	25.1×	+28.76% (above 0%: growing)	n/m	+9.39% (above 0%: growing)	7.96%	(15.41%)	Compare
ACH Accendra Health, Inc.	$20.1M	— (loss-making)	— (loss-making)	−10.07% (below 0%: shrinking)	n/m	−1,624.82% (below 0%: shrinking)	42.95%	(5.73%)	Compare
HKPD Cellyan Biotechnology Co., Ltd	$17.1M	—	—	—	—	−90.45% (below 0%: shrinking)	—	—	Compare
Median of peers	$652.4M	25.2×	20.9×	+6.73%	+16.90%	+10.13%	7.96%	0.00%

All 11 Medical Distribution stocks →

McKesson Corporation (MCK) key facts

Strength: McKesson Corporation’s revenue for fiscal 2026 (year ended March 2026) was $403.4 billion, up 12.4% from fiscal 2025.
Strength: Net income was $5.1 billion, or $38.55 per share (basic), a net margin of 1.18%.
McKesson Corporation (MCK) is a Medical Distribution company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, MCK traded at $1,006.92, a market capitalization of $116.4 billion.
At that price the stock trades at 26.8× trailing-twelve-month earnings and 0.3× sales; its P/E is higher than 66% of its own readings over the past ten years.
McKesson Corporation pays an annual dividend of $3.40 per share, a yield of 0.34%, with a payout ratio of 9.10%.
Return on equity was −274.4% and debt-to-equity -3.83.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 6.15 (safe zone) for fiscal 2026.